Scholarlink

Objective <p>To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).</p> Methods <p>PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included. Methodological quality was assessed independently by two authors. Data on clinical features, neuroimaging patterns and outcomes were analyzed.</p> Results <p>In total, 77 cases from 21 studies were included. Most patients had fever and seizures. Respiratory viruses were common precipitating infection. All patients had bilateral thalamic lesions, and brainstem lesions were more frequently observed in the tocilizumab group (88.0% vs 64.0%, p = 0.04). The length of hospital stay was significantly longer in the tocilizumab group both before (<i>p</i> = 0.01) and after propensity score matching (PSM) (<i>p</i> = 0.02), while the mortality rate was significantly lower in tocilizumab compared with non-tocilizumab group (8.0% vs 33.3%, <i>p</i> = 0.02). Initiation of tocilizumab within 24&#xa0;h was related to a good outcome both before (<i>p</i> &lt; 0.01) and after PSM (<i>p</i> &lt; 0.01). In multivariate regression analysis, elder age and &lt; 24&#xa0;h immunotherapy were independently related with good outcome (age: aOR = 1.35; 95% CI 1.06–1.74, <i>p</i> = 0.02; &lt; 24&#xa0;h immunotherapy: aOR = 8.60; 95% CI 1.08–68.63, <i>p</i> = 0.04). Brainstem lesions was an independent risk factor of poor outcome (aOR = 0.03; 95% CI 0.003–0.29, <i>p</i> &lt; 0.01). Tocilizumab use was independently associated with reduced mortality (aOR = 7.95, 95%CI 1.47–43.03, <i>p</i> = 0.02). No adverse effects were reported.</p> Conclusion <p>This review suggests that timely initiation of tocilizumab therapy within 24&#xa0;h is safe, and may be an effective treatment in ANE, providing a strong rationale for a clinical trial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review

  • 期刊论文

  • 发表日期：

    2025年9月7日

查看全文
  • Yalin Ju,
  • Chang Geng,
  • Hongzhi Guan

摘要

Objective

To evaluate the clinical efficacy of tocilizumab, a interleukin-6 (IL-6) receptor blocker, for the treatment of acute necrotizing encephalopathy (ANE).

Methods

PubMed, Cochrane Library, Embase, and Web of Science were searched for systematic review based on PRISMA guidelines. ANE patients treated with and without tocilizumab were included. Methodological quality was assessed independently by two authors. Data on clinical features, neuroimaging patterns and outcomes were analyzed.

Results

In total, 77 cases from 21 studies were included. Most patients had fever and seizures. Respiratory viruses were common precipitating infection. All patients had bilateral thalamic lesions, and brainstem lesions were more frequently observed in the tocilizumab group (88.0% vs 64.0%, p = 0.04). The length of hospital stay was significantly longer in the tocilizumab group both before (p = 0.01) and after propensity score matching (PSM) (p = 0.02), while the mortality rate was significantly lower in tocilizumab compared with non-tocilizumab group (8.0% vs 33.3%, p = 0.02). Initiation of tocilizumab within 24 h was related to a good outcome both before (p < 0.01) and after PSM (p < 0.01). In multivariate regression analysis, elder age and < 24 h immunotherapy were independently related with good outcome (age: aOR = 1.35; 95% CI 1.06–1.74, p = 0.02; < 24 h immunotherapy: aOR = 8.60; 95% CI 1.08–68.63, p = 0.04). Brainstem lesions was an independent risk factor of poor outcome (aOR = 0.03; 95% CI 0.003–0.29, p < 0.01). Tocilizumab use was independently associated with reduced mortality (aOR = 7.95, 95%CI 1.47–43.03, p = 0.02). No adverse effects were reported.

Conclusion

This review suggests that timely initiation of tocilizumab therapy within 24 h is safe, and may be an effective treatment in ANE, providing a strong rationale for a clinical trial.